Identification of MYC-dependent transcriptional programs in oncogene-addicted liver tumors

Cancer Research

Volumn 76, Issue 12, 2016, Pages 3463-3472

  Kress, Theresia R ^a,b   Pellanda, Paola ^a   Pellegrinet, Luca ^c   Bianchi, Valerio ^a,f   Nicoli, Paola ^b   Doni, Mirko ^b   Recordati, Camilla ^d   Bianchi, Salvatore ^a   Rotta, Luca ^b   Capra, Thelma ^b   Rava, Micol ^a,b   Verrecchia, Alessandro ^b   Radaelli, Enrico ^e   Littlewood, Trevor D ^c   Evan, Gerard I ^c   Amati, Bruno ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Mouse and Animal Pathology Lab   (Italy)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIZ1 PROTEIN; MYC PROTEIN; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE MODEL; EMBRYO; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE REPRESSION; GENETIC TRANSCRIPTION; HEPATOBLASTOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; TRANSGENE; ANIMAL; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; ONCOGENES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC;

EID: 84976875041     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0316     Document Type: Article

References (36)

1. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318-30.
2. Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014;4:pii:a014241.
3. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012;151:56-67.
4. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012;151:68-79.
5. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014;511:488-92.
6. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, et al. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 2014;511:483-7.
7. Guo J, Li T, Schipper J, Nilson KA, Fordjour FK, Cooper JJ, et al. Sequence specificity incompletely defines the genome-wide occupancy of Myc. Genome Biol 2014;15:482.
8. Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 2015;15:593-607.
9. Smith AP, Verrecchia A, Faga G, Doni M, Perna D, Martinato F, et al. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 2009;28:422-30.
10. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008;22:2755-66.
11. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993;72:233-45.
12. Kato GJ, Barrett J, Villa-Garcia M, Dang CV. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 1990;10:5914-20.
13. Tu WB, Helander S, Pilstal R, Hickman KA, Lourenco C, Jurisica I, et al. Myc and its interactors take shape. Biochim Biophys Acta 2015;1849:469-83.
14. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J 2004;23:2830-40.
15. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. Cell 2010;141:432-45.
16. Dunn S, Cowling VH. Myc and mRNA capping. Biochim Biophys Acta 2015;1849:501-5.
17. Lee LA, Dolde C, Barrett J, Wu CS, Dang CV. A link between c-Myc-mediated transcriptional repression and neoplastic transformation. J Clin Invest 1996;97:1687-95.
18. Wiese KE, Haikala HM, von Eyss B, Wolf E, Esnault C, Rosenwald A, et al. Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells. EMBO J 2015;34:1554-71.
19. van Riggelen J, Muller J, Otto T, Beuger V, Yetil A, Choi PS, et al. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010;24:1281-94.
20. Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, et al. The interaction of Myc with Miz1 defines medulloblastoma subgroup identity. Cancer Cell 2016;29:5-16.
21. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and Cancer. Cancer Discov 2015;5:1024-39.
22. Beer S, Zetterberg A, Ihrie RA, McTaggart RA, Yang Q, Bradon N, et al. Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2004;2:e332.
23. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
24. Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, et al. The interaction of Myc with Miz1 defines medulloblastoma subgroup identity. Cancer Cell 2016;29:5-16.
25. Perna D, Faga G, Verrecchia A, Gorski MM, Barozzi I, Narang V, et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene 2012;31:1695-709.
26. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001;414:768-73.
27. Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471-84.
28. Zender L, Xue W, Cordon-Cardo C, Hannon GJ, Lucito R, Powers S, et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol 2005;70:251-61.
29. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 2002;10:509-21.
30. Herkert B, Eilers M. Transcriptional repression: the dark side of myc. Genes Cancer 2010;1:580-6.
31. Gebhardt A, Frye M, Herold S, Benitah SA, Braun K, Samans B, et al. Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1. J Cell Biol 2006;172:139-49.
32. Martinato F, Cesaroni M, Amati B, Guccione E. Analysis of Myc-induced histone modifications on target chromatin. PLoS One 2008;3:e3650.
33. Zeitlinger J, Stark A, Kellis M, Hong JW, Nechaev S, Adelman K, et al. RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. Nat Genet 2007;39:1512-6.
34. Jonkers I, Lis JT. Getting up to speed with transcription elongation by RNA polymerase II. Nat Rev Mol Cell Biol 2015;16:167-77.
35. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011;14:131-42.
36. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016 Mar 10. [Epub ahead of print].